184 related articles for article (PubMed ID: 11844817)
1. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
Kuball J; Wen SF; Leissner J; Atkins D; Meinhardt P; Quijano E; Engler H; Hutchins B; Maneval DC; Grace MJ; Fritz MA; Störkel S; Thüroff JW; Huber C; Schuler M
J Clin Oncol; 2002 Feb; 20(4):957-65. PubMed ID: 11844817
[TBL] [Abstract][Full Text] [Related]
2. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer.
Navai N; Benedict WF; Zhang G; Abraham A; Ainslie N; Shah JB; Grossman HB; Kamat AM; Dinney CP
Ann Surg Oncol; 2016 Nov; 23(12):4110-4114. PubMed ID: 27387678
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
Schuler M; Rochlitz C; Horowitz JA; Schlegel J; Perruchoud AP; Kommoss F; Bolliger CT; Kauczor HU; Dalquen P; Fritz MA; Swanson S; Herrmann R; Huber C
Hum Gene Ther; 1998 Sep; 9(14):2075-82. PubMed ID: 9759934
[TBL] [Abstract][Full Text] [Related]
5. Preferential gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector.
Shimizu H; Akasaka S; Suzuki S; Akimoto M; Shimada T
Urology; 2001 Mar; 57(3):579-84. PubMed ID: 11248651
[TBL] [Abstract][Full Text] [Related]
6. p53 Mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells.
Irie A; Uchida T; Ishida H; Matsumoto K; Iwamura M; Baba S
Mol Urol; 2001; 5(2):53-8. PubMed ID: 11690548
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
9. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer.
Werthman PE; Drazan KE; Rosenthal JT; Khalili R; Shaked A
J Urol; 1996 Feb; 155(2):753-6. PubMed ID: 8558719
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for bladder cancer using adenoviral vector.
Wada Y; Gotoh A; Shirakawa T; Hamada K; Kamidono S
Mol Urol; 2001; 5(2):47-52. PubMed ID: 11690547
[TBL] [Abstract][Full Text] [Related]
12. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.
Dumey N; Mongiat-Artus P; Devauchelle P; Lesourd A; Cotard JP; Le Duc A; Marty M; Cussenot O; Cohen-Haguenauer O
Eur Urol; 2005 Feb; 47(2):257-63. PubMed ID: 15661423
[TBL] [Abstract][Full Text] [Related]
13. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
Siemens DR; Crist S; Austin JC; Tartaglia J; Ratliff T
J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
[TBL] [Abstract][Full Text] [Related]
14. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
Schuler M; Herrmann R; De Greve JL; Stewart AK; Gatzemeier U; Stewart DJ; Laufman L; Gralla R; Kuball J; Buhl R; Heussel CP; Kommoss F; Perruchoud AP; Shepherd FA; Fritz MA; Horowitz JA; Huber C; Rochlitz C
J Clin Oncol; 2001 Mar; 19(6):1750-8. PubMed ID: 11251006
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein.
Benedict WF; Tao Z; Kim CS; Zhang X; Zhou JH; Adam L; McConkey DJ; Papageorgiou A; Munsell M; Philopena J; Engler H; Demers W; Maneval DC; Dinney CP; Connor RJ
Mol Ther; 2004 Sep; 10(3):525-32. PubMed ID: 15336652
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
Irie A; Matsumoto K; Anderegg B; Kuruma H; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
Cancer Gene Ther; 2006 Mar; 13(3):298-305. PubMed ID: 16110311
[TBL] [Abstract][Full Text] [Related]
18. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
19. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
[TBL] [Abstract][Full Text] [Related]
20. Biosafety of in vivo adenovirus-p53 intravesical administration in mice.
Perrotte P; Wood M; Slaton JW; Wilson DR; Pagliaro L; Price RE; Dinney CP
Urology; 2000 Jul; 56(1):155-9. PubMed ID: 10869658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
